Table 4.
Linear regressiona in the different groups (n = 83)
| Variable | Baseline |
Regression coefficient |
||
|---|---|---|---|---|
| Mean eGFR (95% CI) | p value | Change in eGFR per year (95% CI) | p value | |
| All patients | 80.2 (76.0 to 84.4) | 0.51 (–0.30 to 1.33) | ||
| Groups | 0.79 | 0.06 | ||
| ET | 79.5 (73.8 to 85.3) | –0.15 (–1.28 to 0.99) | ||
| PV | 80.2 (73.0 to 87.4) | 1.59 (0.28 to 2.90) | ||
| PMF | 85.7 (67.1 to 104.3) | –1.60 (–4.03 to 0.83) | ||
| Hydroxyurea-treated | 0.03 | 0.33 | ||
| Yes | 76.0 (70.4 to 81.5) | 1.55 (0.56 to 2.54) | ||
| No | 85.4 (79.1 to 91.7) | –0.95 (–2.34 to 0.43) | ||
eGFR, estimated glomerular filtration rate; CI, confidence interval; ET, essential thrombocythemia; PV, polycythemia vera; PMF, primary myelofibrosis.
a
Linear regression of eGFR (mL/min/1.73 m2) versus time (years) in all patients, diagnostic groups, and according to hydroxyurea treatment.